title: Insulin action and glucose metabolism are improved by gemfibrozil treatment in hypertriglyceridemic patients.
abstract: The aim of this study was to determine whether gemfibrozil-mediated decrease in very low density lipoprotein triglyceride (VLDL-TG) concentration is accompanied by an improvement in overall glucose metabolism in hypertriglyceridemic patients. We assessed this hypothesis in 7 hypertriglyceridemic without (HTG) and in 11 hypertriglyceridemic with noninsulin-dependent diabetes mellitus (NIDDM-HTG) who followed three-months treatment either with the drug or with placebo. Placebo VLDL-TG concentrations in both HTG (3.82 +/- 0.92 mmol/l (mean +/- S.D.) vs. 3.91 +/- 1.01 mmol/l) and in NIDDM-HTG (6.62 +/- 3.93 mmol/l vs. 6.84 +/- 4.16 mmol/l) were not different from baseline values, whereas gemfibrozil decreased VLDL-TG in both groups (1.84 +/- 0.56 mmol/l, P < 0.001 for HTG, and 1.93 +/- 2.68 mmol/l, P = 0.013 in NIDDM-HTG). In both groups, gemfibrozil treatment was associated with an improvement in fasting plasma glucose levels (from 5.85 +/- 0.92 mmol/l to 4.87 +/- 0.40 mmol/l in HTG, P = 0.001, and from 11.47 +/- 2.92 mmol/l to 9.56 +/- 3.41 mmol/l in NIDDM-HTG, P = 0.042). In NIDDM-HTG, gemfibrozil treatment was associated with a significantly lower 2 h-postprandial plasma glucose level (9.87 +/- 3.63 vs. 13.09 +/- 3.62, P = 0.05). A significant decrease in fasting free fatty acids (FFA) level was observed during gemfibrozil treatment in both groups, whereas in NIDDM-HTG, a significant drop of these substrates was observed in both fasting and postprandial conditions.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Cattedra di Malattie del Metabolismo, Università degli Studi, Padova, Italy.
authors.forename: A
authors.initials: A
authors.lastname: Avogaro
authors.forename: P
authors.initials: P
authors.lastname: Beltramello
authors.forename: R
authors.initials: R
authors.lastname: Marin
authors.forename: S
authors.initials: S
authors.lastname: Zambon
authors.forename: A
authors.initials: A
authors.lastname: Bonanome
authors.forename: S
authors.initials: S
authors.lastname: Biffanti
authors.forename: L
authors.initials: L
authors.lastname: Confortin
authors.forename: E
authors.initials: E
authors.lastname: Manzato
authors.forename: G
authors.initials: G
authors.lastname: Crepaldi
authors.forename: A
authors.initials: A
authors.lastname: Tiengo
mesh_terms: D001786:Blood Glucose / Q000378:metabolism*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D005260:Female; D015248:Gemfibrozil / Q000627:therapeutic use*; D006801:Humans; D015228:Hypertriglyceridemia / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D007328:Insulin / Q000502:physiology*; D007333:Insulin Resistance; D008079:Lipoproteins, VLDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood
chemical_list: D001786:Blood Glucose; D007328:Insulin; D008079:Lipoproteins, VLDL; D014280:Triglycerides; C030106:very low density lipoprotein triglyceride; D015248:Gemfibrozil